Compare EVEX & TNDM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVEX | TNDM |
|---|---|---|
| Founded | 2020 | 2006 |
| Country | United States | United States |
| Employees | 198 | N/A |
| Industry | Aerospace | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.2M | 1.0B |
| IPO Year | N/A | 2013 |
| Metric | EVEX | TNDM |
|---|---|---|
| Price | $2.43 | $15.19 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 19 |
| Target Price | $6.88 | ★ $28.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.8M |
| Earning Date | 05-05-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,014,736,000.00 |
| Revenue This Year | N/A | $8.11 |
| Revenue Next Year | $11,676.47 | $11.85 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 7.93 |
| 52 Week Low | $2.32 | $10.00 |
| 52 Week High | $7.48 | $29.65 |
| Indicator | EVEX | TNDM |
|---|---|---|
| Relative Strength Index (RSI) | 38.55 | 44.60 |
| Support Level | $2.33 | $13.59 |
| Resistance Level | $3.13 | $16.00 |
| Average True Range (ATR) | 0.16 | 0.81 |
| MACD | -0.00 | 0.02 |
| Stochastic Oscillator | 19.44 | 49.22 |
Eve Holding Inc is a provider of Urban Air Mobility solutions. The company's operating segments are; eVTOL that includes; the design and production of electric vertical take-off and landing vehicles (eVTOLs) including fixed wing and helicopter operators, as well as lessors that purchase and manage aircraft on behalf of operators; Service and Operations Solutions segment which includes a portfolio of maintenance and support services focused on its and third-party eVTOLs; and the UATM segment, a new Urban Air Traffic Management system designed to allow eVTOLs to operate safely and efficiently in dense urban airspace alongside conventional aircraft and drones.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.